Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.

[1]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[2]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[3]  T. Choueiri,et al.  Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  R. Figlin,et al.  Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) , 2006 .

[5]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[6]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[8]  A. Ravaud,et al.  Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie , 2005, World Journal of Urology.

[9]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Lai,et al.  Metaplastic breast cancer: Clinical traits and outcomes , 2004 .

[11]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Bukowski,et al.  1098 Phase III study of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy , 2003 .

[13]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[14]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[15]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Tammela,et al.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[19]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Trump,et al.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.

[21]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[22]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .